Drug Interaction Study With Proton Pump Inhibitor - Full Text View

Sponsor:	Bristol-Myers Squibb
Information provided by:	Bristol-Myers Squibb
ClinicalTrials.gov Identifier:	NCT00357240

Purpose

The purpose of this clinical research study is to assess the effect of omeprazole at 20 mg on the pharmacokinetics of atazanavir administered as atazanavir with ritonavir relative to atazanavir or atazanavir/ritonavir in the absence of omeprazole in healthy subjects.

Condition	Intervention	Phase
HIV Infections	Drug: Atazanavir Drug: Atazanavir/Ritonavir Drug: Atazanavir/Ritonavir+Omeprazole	Phase I

Study Type:	Interventional
Study Design:	Randomized, Open Label, Active Control, Parallel Assignment, Pharmacokinetics Study
Official Title:	Randomized, Open-Label, Multiple-Dose Study to Evaluate the Effect of Omeprazole 20 mg on the Pharmacokinetics of Atazanavir Administered With Ritonavir in Healthy Subjects

Resource links provided by NLM:

MedlinePlus related topics: AIDS

Drug Information available for: Omeprazole Omeprazole magnesium Ritonavir Esomeprazole Sodium Esomeprazole magnesium BMS 232632 Atazanavir sulfate

U.S. FDA Resources

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:

Effect of omeprazole 20 mg on PK of atazanavir (with ritonavir), coadministered or temporally separated, in healthy subjects.

Secondary Outcome Measures:

PK of ritonavir and omeprazole. Safety and tolerability of atazanavir +/- ritonavir, +/- omeprazole.

Estimated Enrollment:	56
Study Start Date:	June 2006

Arms	Assigned Interventions
A1: Active Comparator	Drug: Atazanavir Capsules, Oral, 400 mg, once daily, 6 days.
A2: Active Comparator	Drug: Atazanavir/Ritonavir Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
A3 I: Experimental	Drug: Atazanavir/Ritonavir+Omeprazole Capsules/capsules + Capsules, Oral, 300/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
A3 II: Experimental	Drug: Atazanavir/Ritonavir+Omeprazole Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
B1: Active Comparator	Drug: Atazanavir Capsules, Oral, 400 mg, once daily, 6 days.
B2: Active Comparator	Drug: Atazanavir/Ritonavir Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
B3 I: Experimental	Drug: Atazanavir/Ritonavir+Omeprazole Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in AM, 7 days.
B3 II: Experimental	Drug: Atazanavir/Ritonavir+Omeprazole Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in PM, 7 days.

Eligibility

Ages Eligible for Study:	18 Years to 50 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Healthy male and female subjects between the ages of 18 to 50 years old with BMI 18 to 32 kg/m2

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00357240

Locations

United States, New Jersey
Local Institution
Hamilton, New Jersey, United States

Sponsors and Collaborators

Bristol-Myers Squibb

Investigators

Study Director:

Bristol-Myers Squibb

More Information

Additional Information:

BMS Clinical Trials Disclosure This link exits the ClinicalTrials.gov site

For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	AI424-288
Study First Received:	July 25, 2006
Last Updated:	June 27, 2008
ClinicalTrials.gov Identifier:	NCT00357240 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Bristol-Myers Squibb:

Protease inhibitor

Additional relevant MeSH terms:

Anti-Infective Agents
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Molecular Mechanisms of Pharmacological Action
Omeprazole
Infection
Anti-Retroviral Agents
Proton Pump Inhibitors
Therapeutic Uses
Anti-Ulcer Agents
Retroviridae Infections
RNA Virus Infections
HIV Protease Inhibitors
Anti-HIV Agents

Immune System Diseases
Acquired Immunodeficiency Syndrome
Gastrointestinal Agents
Atazanavir
Enzyme Inhibitors
Antiviral Agents
Immunologic Deficiency Syndromes
Pharmacologic Actions
Protease Inhibitors
Virus Diseases
HIV Infections
Ritonavir
Sexually Transmitted Diseases
Lentivirus Infections

ClinicalTrials.gov processed this record on February 08, 2010